Rankings · Price against the business

Most free cash flow per dollar of price

Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.

125 companies meet this test

Figures as of November 15, 2026

#CompanyGradeFree cash flow yieldP/ERevenue growthMarket value
1GMABGenmab A/SB+35.7%3.34+18% a year$3.2B
2NRIXNURIX THERAPEUTICS, INC.A+21.9%6.73—$1.7B
3BCRXBIOCRYST PHARMACEUTICALS, INC.B18.7%—+45% a year$2B
4HRMYHARMONY BIOSCIENCES HOLDINGS, INC.B+17.5%11.14+22% a year$2B
5TAKTakeda Pharmaceutical Company LimitedA16.0%50.12+3% a year$34.4B
6GRFSGrifols SAA14.8%33.82+7% a year$5.9B
7THCTENET HEALTHCARE CORPA+14.6%8.30+3% a year$22.8B
8SNYSanofiB13.7%6.80+4% a year$59B
9ANIPANI PHARMACEUTICALS, INCB+13.3%14.26+32% a year$1.5B
10PCRXPACIRA BIOSCIENCES, INC.B11.6%39.20+4% a year$1.5B

More rankings

A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.